Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Natalia Palazón-CarriónAlejandro Martín García-SanchoEsteban Nogales-FernándezCarlos Jiménez-CorteganaFernando Carnicero-GonzálezEduardo Ríos-HerranzFátima de la Cruz-VicenteGuillermo Rodríguez-GarcíaRubén Fernández-ÁlvarezNatividad Martínez-BanaclochaJosep Gumà PadróJosé Gómez-CodinaAntonio Salar-SilvestreDelvys Rodríguez-AbreuLaura Gálvez CarvajalJorge Labrador-GomezMaría Guirado-RisueñoDaniel José García-DomínguezLourdes Hontecillas-PrietoPablo Espejo-GarcíaIsabel Fernández-RománMariano Provencio PullaMargarita Sánchez-BeatoMarta NavarroMarylène LejeuneTomás Álvaro-NaranjoMaria Casanova-EspinosaVíctor Sánchez-MargaletAntonio Rueda-DomínguezLuis de la Cruz MerinoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
R2-GDP schedule is feasible and highly active in R/R DLBCL, including the primary refractory population. Immune biomarkers showed differences in responders versus progressors.